文拉法辛合并抗精神病药治疗精神分裂症阴性症状的临床研究

The clinical study about Venlafaxine combined with antipsychotics in treatment of the negative symptoms of schizophrenia

目的探讨文拉法辛合并抗精神病药治疗精神分裂症阴性症状的疗效和不良反应。方法对符合入组标准的60例精神分裂症患者随机分为两组，每组30例，研究组为在原用抗精神病药治疗不变的基础上，联用文拉法辛50～200mg／d，疗程12周，对照组仍维持原有的治疗方案。采用阳性和阴性症状量表（PANSS）和治疗中出现的症状量表（TESS）评定疗效及不良反应，于治疗前和治疗4、8、12周末分别进行评分。同时检查血、尿常规、肝、肾功能，心电图．．结果治疗第12周末，研究组PANSS总分减分率为（21．6±6．5）％，阴性因子分减分率为（29．7±2．7）％；对照组分别为（11．1±1．7）％和（2．5±0．9）％，两者差异有统计学意义（P〈0．01）。研究组各阴性因子评分比治疗前明显降低，其减分率均高于对照组各条目。研究组与对照组TESS评分差异无统计学意义（P〉0．05）。结论文拉法辛合并抗精神病药治疗精神分裂症阴性症状疗效肯定，安全可靠。

Objective To explore the efficacy and safety of venlafaxine combined with antipsychoties in treatment of the Negative symp- toms of schizophrenia. Methods 60 schizophrenia patients who were fit with the standard were randomly divided into studied groups （ treated with the original antipsyehotics and venlafaxine ） and controlled group （ treated with the original antipsychotics ）. The course of treatment was twelve weeks. The efficiency and side effects were evaluated by positive and negative symptoms scale （PANSS） and treatment emergent symp- toms scale （TESS） before and after treatments for4,8,12 weeks. At the same time, we checked the blood and urine test, liver and renal func- tion and the electrocardiogram. Results The reduction on PANSS score and on negative symptom scale at weeks 12 were （21.6 ± 6.5 ） and （29.7 ± 2.7） in venlafaxine combined group, which were higher than that in controlled group （ 11.1 ± 1.7 and 2. 5 ± 0. 9, P 〈 0. 01 ）. There were no significant differences between the two groups on The TESS. Conclusion It is suggested that venlafaxine in combination with antipsychotics is effective and safe in treatment of the negative symptom in schizophrenia patients.